ADMA Biologics (NASDAQ:ADMA) Shares Gap Up on Strong Earnings

Shares of ADMA Biologics Inc (NASDAQ:ADMA) gapped up before the market opened on Thursday after the company announced better than expected quarterly earnings. The stock had previously closed at $10.48, but opened at $12.01. ADMA Biologics shares last traded at $13.0440, with a volume of 1,753,292 shares.

The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.03. The business had revenue of $141.10 million for the quarter, compared to analysts’ expectations of $138.11 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%. The firm’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.15 earnings per share.

Key Stories Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Q3 revenue was $141.1 million, ahead of the $138.1 million consensus estimate, while adjusted EPS of $0.23 topped the $0.20 forecast. Revenue grew 5% year over year, and GAAP net income rose 37% to $49.9 million. ADMA Biologics Q3 results
• Positive Sentiment: ASCENIV revenue climbed 31% to $124.7 million, and gross margin expanded to 71% from a year earlier, supporting improved profitability and operating leverage. Q3 earnings and ASCENIV coverage
• Positive Sentiment: The company reiterated its 2026 revenue outlook of at least $530 million and raised its minimum adjusted EBITDA outlook to at least $275 million, citing accelerating ASCENIV demand. ADMA outlook update
• Neutral Sentiment: Cantor Fitzgerald raised its price target from $12 to $13 but kept a neutral rating, signaling a higher valuation objective without a more bullish analyst stance. Cantor Fitzgerald recommendations

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Mizuho set a $18.00 price target on shares of ADMA Biologics in a research report on Thursday. Cantor Fitzgerald increased their price objective on shares of ADMA Biologics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Thursday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research note on Monday, September 14th. Finally, Zacks Research raised shares of ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 2nd. Three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, ADMA Biologics currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.50.

Hedge Funds Weigh In On ADMA Biologics

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of ADMA Biologics during the 2nd quarter worth about $321,037,000. Dimensional Fund Advisors LP increased its stake in shares of ADMA Biologics by 3.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 5,005,481 shares of the biotechnology company’s stock valued at $45,101,000 after acquiring an additional 169,843 shares during the last quarter. Bank of America Corp DE increased its stake in shares of ADMA Biologics by 107.5% in the 1st quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company’s stock valued at $36,019,000 after acquiring an additional 2,071,338 shares during the last quarter. Nantahala Capital Management LLC acquired a new stake in shares of ADMA Biologics in the 2nd quarter valued at approximately $19,753,141. Finally, Ranger Investment Management L.P. acquired a new stake in shares of ADMA Biologics in the 2nd quarter valued at approximately $17,706,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Up 23.1%

The firm’s 50 day moving average is $10.07 and its two-hundred day moving average is $10.93. The firm has a market cap of $2.89 billion, a P/E ratio of 18.42 and a beta of 0.65. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company’s activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases.

ADMA’s portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency.